| 45.91 0.09 (0.2%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 55.29 | 1-year : | 64.58 |
| Resists | First : | 47.34 | Second : | 55.29 |
| Pivot price | 44.52  |
|||
| Supports | First : | 43.59 | Second : | 41.28 |
| MAs | MA(5) : | 45.68 |
MA(20) : | 44.66 |
| MA(100) : | 42.87 |
MA(250) : | 41.37 |
|
| MACD | MACD : | 0 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 88.6  |
D(3) : | 87.9 |
| RSI | RSI(14): 53.6 |
|||
| 52-week | High : | 60.59 | Low : | 27 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PTGX ] has closed below upper band by 21.7%. Bollinger Bands are 46.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 46.08 - 46.27 | 46.27 - 46.42 |
| Low: | 44.67 - 44.9 | 44.9 - 45.09 |
| Close: | 45.52 - 45.89 | 45.89 - 46.21 |
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Wed, 21 May 2025
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 | PTGX Stock News - GuruFocus
Wed, 21 May 2025
Exclusive: Protagonist Therapeutics CEO Reveals Company Strategy at Major Jefferies Healthcare Conference - Stock Titan
Fri, 09 May 2025
Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance
Tue, 06 May 2025
Protagonist Hits Major Clinical Win: Phase 3 Trial Success Sets Stage for Two FDA Filings in 2025 - Stock Titan
Tue, 06 May 2025
Protagonist Therapeutics, Inc SEC 10-Q Report - TradingView
Tue, 06 May 2025
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 103 (%) |
| Shares Short | 6,120 (K) |
| Shares Short P.Month | 4,710 (K) |
| EPS | 0.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.13 |
| Profit Margin | 27 % |
| Operating Margin | -68.2 % |
| Return on Assets (ttm) | 2.4 % |
| Return on Equity (ttm) | 8.9 % |
| Qtrly Rev. Growth | -89 % |
| Gross Profit (p.s.) | 3.35 |
| Sales Per Share | 3.35 |
| EBITDA (p.s.) | 0.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 337 (M) |
| Levered Free Cash Flow | 328 (M) |
| PE Ratio | 58.85 |
| PEG Ratio | 0 |
| Price to Book value | 4.12 |
| Price to Sales | 13.69 |
| Price to Cash Flow | 8.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|